Evidence map›Paper›PMID 34851666›Full record

ArticleScience advances2021

ssDNA nanotubes for selective targeting of glioblastoma and delivery of doxorubicin for enhanced survival.

Michael A Harris, Huihui Kuang, Zachary Schneiderman, Maple L Shiao, Andrew T Crane, Matthew R Chrostek, Alexandru-Flaviu Tăbăran, Thomas Pengo, Kevin Liaw, Beibei Xu and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Nanomedicine for Glioblastoma Therapy: Novel Insights and Future Perspectives.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Michael A HarrisDepartment of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-7709-6798
Huihui KuangInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD 21218, USA.
Zachary SchneidermanInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD 21218, USA.ORCID 0000-0001-7596-8276
Maple L ShiaoDepartment of Neurosurgery, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
Andrew T CraneDepartment of Neurosurgery, University of Minnesota Medical School, Minneapolis, MN 55455, USA.ORCID 0000-0003-3452-2766
Matthew R ChrostekDepartment of Neurosurgery, University of Minnesota Medical School, Minneapolis, MN 55455, USA.ORCID 0000-0002-9457-1431
Alexandru-Flaviu TăbăranComparative Pathology Shared Resource, Masonic Cancer Center, University of Minnesota, Saint Paul, MN 55108, USA.ORCID 0000-0001-5744-0451
Thomas PengoUniversity of Minnesota Informatics Institute, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-9632-918X
Kevin LiawDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.ORCID 0000-0002-8235-1407
Beibei XuDepartment of Neurosurgery, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
Lucy LinInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD 21218, USA.ORCID 0000-0001-8104-5400
Clark C ChenDepartment of Neurosurgery, University of Minnesota Medical School, Minneapolis, MN 55455, USA.ORCID 0000-0001-9544-2570
M Gerard O'SullivanComparative Pathology Shared Resource, Masonic Cancer Center, University of Minnesota, Saint Paul, MN 55108, USA.ORCID 0000-0002-5463-1153
Rangaramanujam M KannanDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.ORCID 0000-0002-3712-7836
Walter C LowDepartment of Neurosurgery, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
Efrosini KokkoliInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD 21218, USA.ORCID 0000-0001-7783-0158

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Effective treatment of glioblastoma remains a daunting challenge. One of the major hurdles in the development of therapeutics is their inability to cross the blood-brain tumor barrier (BBTB). Local delivery is an alternative approach that can still suffer from toxicity in the absence of target selectivity. Here, we show that nanotubes formed from self-assembly of ssDNA-amphiphiles are stable in serum and nucleases. After bilateral brain injections, nanotubes show preferential retention by tumors compared to normal brain and are taken up by glioblastoma cells through scavenger receptor binding and macropinocytosis. After intravenous injection, they cross the BBTB and internalize in glioblastoma cells. In a minimal residual disease model, local delivery of doxorubicin showed signs of toxicity in the spleen and liver. In contrast, delivery of doxorubicin by the nanotubes resulted in no systemic toxicity and enhanced mouse survival. Our results demonstrate that ssDNA nanotubes are a promising drug delivery vehicle to glioblastoma.

Identifiers

PMID34851666
PMCPMC8635432

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.